Galixir Inc. has reported serine/threonine‑protein kinase ULK1/ULK2 inhibitors potentially useful for the treatment of cancer.

Simcere Zaiming Pharmaceutical Co. Ltd. has described membrane‑associated tyrosine‑ and threonine‑specific Cdc2‑inhibitory kinase (PKMYT1) inhibitors for cancer.

Guangzhou Runer Ophthalmic Biotechnology Co. Ltd. has identified phenyl heterocyclic compounds acting as retinol‑binding protein 4 (RBP4)/transthyretin (TTR) interaction inhibitors.

Amgen Inc. has synthesized new GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Washington University in St. Louis has disclosed new autophagy inducers reported to be useful for the treatment of alpha-1 antitrypsin deficiency, amyotrophic lateral sclerosis, Alzheimer’s, Huntington’s and Parkinson’s disease.

Domain Therapeutics SA has prepared and tested new azine-based compounds acting as proteinase-activated receptor 2 (F2RL1; PAR2) inhibitors reported to be useful for the treatment of allergy, autoimmune, metabolic diseases, cardiovascular, dermatological, inflammatory disorders, pain and cancer.

Work at Pharmaengine Inc. has led to the identification of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Muna Therapeutics ApS has patented new triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes and obesity, among others.

Astrazeneca AB has patented new proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors reported to be useful for the treatment of cardiovascular disorders.

Mitochondrial glutaminase kidney isoform (GLS, GLS1) inhibitors have been detailed in a Sitryx Therapeutics Ltd. patent. They are described as potentially useful for the treatment of fibrosis and inflammatory disorders.